Developer docs
API playgroundTry for free, no card

Search company profiles

Iksuda Therapeutics

Full company profile

uuid0002bv1

Namestring
Iksuda Therapeutics
Legal namestring
Iksuda Therapeutics Limited
Websiteurl
iksuda.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Iksuda Therapeutics is a clinical-stage biotechnology company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Founded in 2007 as Glythera Ltd and rebranded in 2018, the company is headquartered in Newcastle upon Tyne, UK, with US operations in Boston, MA. Iksuda's pipeline comprises two clinical-stage programs—IKS014 (HER2-directed, Phase 1 dose expansion) and IKS03 (CD19-directed, Phase 1 first patient dosed May 2025)—along with preclinical assets IKS04 (CA242, GI tumors) and IKS073 (B7H3, first ProAlk-containing ADC). Phase 1 IKS014 data have shown a 64% ORR in advanced breast cancer patients and a 50% ORR in pre-treated HER2+ esophageal cancer patients, with a preclinical therapeutic index of 12 versus less than 1.5 for Kadcyla and less than 3 for Enhertu.

The company's technology stack is built on three modular platforms: (1) PermaLink, a proprietary vinyl-pyridine cysteine-specific bioconjugation chemistry delivering market-leading plasma stability; (2) ProAlk, a first-in-class protein alkylating payload class (licensed from the University of Goettingen) offering a novel mechanism of action distinct from tubulin inhibitors and DNA cross-linkers, with MDR resistance and bystander activity; and (3) tumor-selective glucuronide-driven payload activation, clinically validated through IKS014 and CS5001. Iksuda also uses the ConjuAll site-specific homogeneous conjugation platform licensed from LegoChem Biosciences. ADC programs are designed for maximum anti-cancer impact and a wide therapeutic index by combining the optimal binder, linker, and payload for each target.

Iksuda's business model is licensing- and partnership-driven. The company generates non-dilutive capital through platform and program out-licensing (e.g., IKS014 licensed as FS-1502 to Fosun Pharma for Greater China), with development, regulatory, and commercial milestone payments plus royalties. It also raises equity financing (cumulative disclosed funding of approximately $49.2M, including a $47M Series A in June 2021 co-led by Mirae Asset Capital and Celltrion). The company has not yet generated product revenue. Its primary customers are pharmaceutical and biotechnology partners seeking ADC development expertise and licenses, with the end-patient focus being oncology patients with solid tumors and B-cell malignancies who have relapsed on or are refractory to standard of care.

Short descriptiontext

Iksuda Therapeutics is a clinical-stage UK biotech developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, leveraging proprietary PermaLink bioconjugation and ProAlk payload platforms. It serves oncology patients with relapsed/refractory solid tumors and B-cell malignancies through licensing partnerships with major pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics development, bioconjugation platforms, ADC drug development, tumor-selective payloads
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Antibody-Drug Conjugates (ADC) Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1ADC Drug Development & Commercialization
TypeLicensing Royalties
Description

Iksuda is a clinical-stage biotech developing a pipeline of differentiated ADCs for hard-to-treat cancers. The company has not yet generated product revenue. Future revenue is expected from global commercialization of its proprietary ADC pipeline, either independently or through co-development partnerships, targeting hematological and solid tumor indications with high unmet need.

iksuda.com
2Licensing & Partnership Deals
TypeLicensing Royalties
Description

Iksuda generates non-dilutive capital through licensing agreements for its proprietary platforms (PermaLink, ProAlk) and ADC programs. The company has in-licensed programs (IKS03 from LegoChem, IKS014 from LegoChem) and out-licensed regional rights (FS-1502/IKS014 to Fosun Pharma for Greater China). Partnerships include development, regulatory, and commercial milestone payments plus royalties on sales.

iksuda.com
3Equity Financing
TypeLicensing Royalties
Description

The company has raised equity capital to fund R&D and clinical development. Completed a $47M (approx. £34M) Series A financing round in June 2021, co-led by Mirae Asset Capital and Celltrion. Prior seed and venture rounds include £2M in 2012 and £700K in 2013. No public market listing as of the available data.

iksuda.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Iksuda Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Its pipeline includes clinical-stage programs IKS014 (HER2-directed, Phase 1) and IKS03 (CD19-directed, Phase 1) plus preclinical IKS04 and IKS073, all built on the proprietary PermaLink bioconjugation platform, ProAlk protein alkylating payload class, and tumor-selective glucuronide cleavable linkers. The company commercializes its ADC programs and platforms through global licensing deals and independent clinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IKS014 Phase 1: ORR of 64% in 11 advanced breast cancer patients at doses ≥90 mg/m², including responses in patients previously treated with Enhertu; ORR of 50% in 10 pre-treated HER2+ esophageal cancer patients; clinical benefit rate of 80% in esophageal cancer patients.
+3 more records
Product overview1 text field

Iksuda Therapeutics is a clinical-stage biotech company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. The company's portfolio includes two clinical-stage ADCs (IKS03 and IKS014), two preclinical programs (IKS04 and IKS073), and an expanding discovery-stage pipeline of ProAlk-ADCs. The ADC platform combines tumor-selective payload activation technology using glucuronide linkers, multiple payload classes (PBD, MMAF, and proprietary ProAlk protein alkylators), and stable bioconjugation platforms (proprietary PermaLink and licensed ConjuAll).

Product and service6 records
1IKS03
CategoryClinical-stage ADC product
Description

CD19-directed ADC in Phase 1 clinical trials for B-cell malignancies including DLBCL and Mantle Cell Lymphoma, using a tumor-selective glucuronide linker with PBD prodrug payload and showing class-leading therapeutic index (preclinical TI >5 vs. <1 for Zynlonta and <1.2 for Polivy). Licensed-in from LegoChem Biosciences (originally LCB73).

2IKS014
CategoryClinical-stage ADC product
Description

HER2-directed ADC in Phase 1 dose expansion for HER2+ solid tumors including breast, gastric, lung, and esophageal cancers. Uses MMAF payload with glucuronide linker technology for improved safety profile. Licensed-in from LegoChem Biosciences; out-licensed to Fosun Pharma as FS-1502 for Greater China.

3IKS04
CategoryPreclinical ADC product
Description

CA242 (CanAg)-directed ADC in preclinical/IND-enabling studies for GI tumors including colorectal, pancreatic, gastric, and bladder cancers. Uses ultra-low DAR approach with PBD prodrug payload to improve tumor penetration in high-expression tumors.

4IKS073
CategoryPreclinical ADC product
Description

B7H3-directed ADC in IND-enabling studies for solid tumors including lung, esophageal, head & neck, colorectal, stomach, breast, and cervix. First ADC to incorporate Iksuda's proprietary ProAlk protein alkylating payload with novel mechanism.

5ProAlk Payload Platform
CategoryADC platform technology (licensable)
Description

Proprietary first-in-class protein alkylating payload class for ADCs available for licensing to pharma partners. Exerts cell-killing activity through alkylation of cytosolic proteins rather than DNA cross-linking, used in prodrug format with glucuronide triggers for tumor-selective activation. MDR-resistant with potent bystander activity.

6PermaLink Bioconjugation Platform
CategoryADC platform technology (licensable)
Description

Proprietary ultra-stable cysteine-specific bioconjugation chemistry platform using vinyl-pyridine approach, available for licensing against selected targets of interest. Delivers market-leading ADC plasma stability with minimal DAR decrease over time, and is compatible with a broad range of payloads.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-10
Description

License and commercialization agreement for LCB's HER2 ADC program (LCB14, now IKS014). Iksuda gained exclusive worldwide rights excluding Greater China and South Korea. Agreement includes development, regulatory, and commercial milestone payments plus royalties on commercial sales. LCB also licensed IKS014 to Fosun Pharma for Greater China.

2University of Goettingen
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-10-13
Description

Exclusive worldwide licensing agreement for a novel class of tumor-activated prodrug payloads with protein alkylating cytotoxicity (ProAlk series). Partnership founded on successful collaboration exemplifying the series in ADC formats. The novel protein alkylating mode of action differs from DNA cross-linking, conferring benefits against drug resistance mechanisms.

iksuda.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-05-18
Description

Licensing agreement for LCB's anti-CD19 ADC program (LCB73, now IKS03) for B-cell cancers including DLBCL and Burkitt lymphoma. Iksuda gained worldwide rights for development and commercialization. IKS03 delivers a tumor-activated prodrug PBD payload with preclinical data showing best-in-class TI over comparators.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-04-16
Description

Multi-target research collaboration and license agreement granting Iksuda access to LCB's next-generation PBD prodrug payload and proprietary linker (ConjuAll platform) for up to three undisclosed targets. Iksuda gained rights to research, develop, and commercialize targeted anti-cancer therapeutics using LCB's technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-16
Description

Expanded license agreement granting Iksuda access to LCB's next-generation ADC platform technology for up to six targets, supplementing the tumor-activated payloads accessed in the 2020 licensing agreement. The expansion included LCB's new payload technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC biotech developing ADCs for hematologic and solid tumors, with multiple Phase 1/2 programs and a similar pipeline-based business model. Most directly comparable in stage, modality focus, and go-to-market approach.

TypeDirect peer
Description

Clinical-stage ADC biotech with proprietary payload platforms (e.g., Dolasynthen, Immunosynthen) targeting oncology. Closely comparable as a platform-based ADC developer with multiple proprietary payload classes and clinical-stage assets.

TypeDirect peer
Description

European clinical-stage ADC biotech with proprietary bioconjugation and payload platforms. Highly comparable in technology strategy (proprietary linkers + payloads) and European clinical-stage positioning.

TypeDirect peer
Description

German clinical-stage ADC biotech with a proprietary amanitin-based payload platform (similar to Iksuda's ProAlk in offering a novel payload MoA). Closely comparable as a European platform-based ADC developer pursuing first-in-class payload differentiation.

TypeDirect peer
Description

Clinical-stage oncology biotech developing immune-stimulating ADCs. Comparable as a clinical-stage ADC innovator with proprietary platform technology, though focused on immune stimulation rather than cytotoxic payloads.

TypeDirect peer
Description

Clinical-stage oncology biotech with ADC and immuno-oncology programs. Comparable as a multi-program clinical-stage ADC developer pursuing novel linker and payload strategies.

TypeDirect peer
Description

Clinical-stage ADC biotech developing ADCs for solid tumors with proprietary conjugation technology. Comparable in clinical-stage ADC focus and platform-based differentiation approach.

TypeBroad incumbent
Description

Pioneer of ADC technology and developer of Kadcyla (where Iksuda CSO Bob Lutz led development). Acquired by AbbVie in 2024. Broad incumbent reference point for ADC platform validation and competitive context.

TypeRegional player
Description

Chinese biopharmaceutical company with a growing ADC pipeline. Comparable as a Chinese-market ADC developer analogous to Fosun Pharma's regional role with IKS014 (FS-1502).

TypeOthers
Description

ADC-focused contract development and manufacturing organization (CDMO). Comparable as an ecosystem participant that supports ADC developers like Iksuda with conjugation and manufacturing services, providing a market context for ADC development economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iksuda Therapeutics

Antibody-Drug Conjugates (ADC) Therapeuticsiksuda.com

Iksuda Therapeutics is a clinical-stage UK biotech developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, leveraging proprietary PermaLink bioconjugation and ProAlk payload platforms. It serves oncology patients with relapsed/refractory solid tumors and B-cell malignancies through licensing partnerships with major pharma.

What Iksuda Therapeutics does

Iksuda Therapeutics is a clinical-stage biotechnology company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Founded in 2007 as Glythera Ltd and rebranded in 2018, the company is headquartered in Newcastle upon Tyne, UK, with US operations in Boston, MA. Iksuda's pipeline comprises two clinical-stage programs—IKS014 (HER2-directed, Phase 1 dose expansion) and IKS03 (CD19-directed, Phase 1 first patient dosed May 2025)—along with preclinical assets IKS04 (CA242, GI tumors) and IKS073 (B7H3, first ProAlk-containing ADC). Phase 1 IKS014 data have shown a 64% ORR in advanced breast cancer patients and a 50% ORR in pre-treated HER2+ esophageal cancer patients, with a preclinical therapeutic index of 12 versus less than 1.5 for Kadcyla and less than 3 for Enhertu.

The company's technology stack is built on three modular platforms: (1) PermaLink, a proprietary vinyl-pyridine cysteine-specific bioconjugation chemistry delivering market-leading plasma stability; (2) ProAlk, a first-in-class protein alkylating payload class (licensed from the University of Goettingen) offering a novel mechanism of action distinct from tubulin inhibitors and DNA cross-linkers, with MDR resistance and bystander activity; and (3) tumor-selective glucuronide-driven payload activation, clinically validated through IKS014 and CS5001. Iksuda also uses the ConjuAll site-specific homogeneous conjugation platform licensed from LegoChem Biosciences. ADC programs are designed for maximum anti-cancer impact and a wide therapeutic index by combining the optimal binder, linker, and payload for each target.

Iksuda's business model is licensing- and partnership-driven. The company generates non-dilutive capital through platform and program out-licensing (e.g., IKS014 licensed as FS-1502 to Fosun Pharma for Greater China), with development, regulatory, and commercial milestone payments plus royalties. It also raises equity financing (cumulative disclosed funding of approximately $49.2M, including a $47M Series A in June 2021 co-led by Mirae Asset Capital and Celltrion). The company has not yet generated product revenue. Its primary customers are pharmaceutical and biotechnology partners seeking ADC development expertise and licenses, with the end-patient focus being oncology patients with solid tumors and B-cell malignancies who have relapsed on or are refractory to standard of care.

Iksuda Therapeutics firmographics

Firmographics
Name
Iksuda Therapeutics
Legal name
Iksuda Therapeutics Limited
Website
https://iksuda.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Iksuda Therapeutics is a clinical-stage UK biotech developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, leveraging proprietary PermaLink bioconjugation and ProAlk payload platforms. It serves oncology patients with relapsed/refractory solid tumors and B-cell malignancies through licensing partnerships with major pharma.
Ownership category
akta.pro rank

Iksuda Therapeutics industry classification

Industry
Product category
Antibody-Drug Conjugates (ADC) Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics development
  • Bioconjugation platforms
  • ADC drug development
  • Tumor-selective payloads

Where Iksuda Therapeutics is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Iksuda Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ADC Drug Development & Commercialization: Iksuda is a clinical-stage biotech developing a pipeline of differentiated ADCs for hard-to-treat cancers. The company has not yet generated product revenue. Future revenue is expected from global commercialization of its proprietary ADC pipeline, either independently or through co-development partnerships, targeting hematological and solid tumor indications with high unmet need.
  2. Licensing & Partnership Deals: Iksuda generates non-dilutive capital through licensing agreements for its proprietary platforms (PermaLink, ProAlk) and ADC programs. The company has in-licensed programs (IKS03 from LegoChem, IKS014 from LegoChem) and out-licensed regional rights (FS-1502/IKS014 to Fosun Pharma for Greater China). Partnerships include development, regulatory, and commercial milestone payments plus royalties on sales.
  3. Equity Financing: The company has raised equity capital to fund R&D and clinical development. Completed a $47M (approx. £34M) Series A financing round in June 2021, co-led by Mirae Asset Capital and Celltrion. Prior seed and venture rounds include £2M in 2012 and £700K in 2013. No public market listing as of the available data.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Iksuda Therapeutics product offering

Product offering

Core offering

Iksuda Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Its pipeline includes clinical-stage programs IKS014 (HER2-directed, Phase 1) and IKS03 (CD19-directed, Phase 1) plus preclinical IKS04 and IKS073, all built on the proprietary PermaLink bioconjugation platform, ProAlk protein alkylating payload class, and tumor-selective glucuronide cleavable linkers. The company commercializes its ADC programs and platforms through global licensing deals and independent clinical development.

Product overview

Iksuda Therapeutics is a clinical-stage biotech company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. The company's portfolio includes two clinical-stage ADCs (IKS03 and IKS014), two preclinical programs (IKS04 and IKS073), and an expanding discovery-stage pipeline of ProAlk-ADCs. The ADC platform combines tumor-selective payload activation technology using glucuronide linkers, multiple payload classes (PBD, MMAF, and proprietary ProAlk protein alkylators), and stable bioconjugation platforms (proprietary PermaLink and licensed ConjuAll).

Differentiator

Problem solved

Functional benefit

Products and services

  • IKS03 CD19-directed ADC in Phase 1 clinical trials for B-cell malignancies including DLBCL and Mantle Cell Lymphoma, using a tumor-selective glucuronide linker with PBD prodrug payload and showing class-leading therapeutic index (preclinical TI >5 vs. <1 for Zynlonta and <1.2 for Polivy). Licensed-in from LegoChem Biosciences (originally LCB73).
  • IKS014 HER2-directed ADC in Phase 1 dose expansion for HER2+ solid tumors including breast, gastric, lung, and esophageal cancers. Uses MMAF payload with glucuronide linker technology for improved safety profile. Licensed-in from LegoChem Biosciences; out-licensed to Fosun Pharma as FS-1502 for Greater China.
  • IKS04 CA242 (CanAg)-directed ADC in preclinical/IND-enabling studies for GI tumors including colorectal, pancreatic, gastric, and bladder cancers. Uses ultra-low DAR approach with PBD prodrug payload to improve tumor penetration in high-expression tumors.
  • IKS073 B7H3-directed ADC in IND-enabling studies for solid tumors including lung, esophageal, head & neck, colorectal, stomach, breast, and cervix. First ADC to incorporate Iksuda's proprietary ProAlk protein alkylating payload with novel mechanism.
  • ProAlk Payload Platform Proprietary first-in-class protein alkylating payload class for ADCs available for licensing to pharma partners. Exerts cell-killing activity through alkylation of cytosolic proteins rather than DNA cross-linking, used in prodrug format with glucuronide triggers for tumor-selective activation. MDR-resistant with potent bystander activity.
  • PermaLink Bioconjugation Platform Proprietary ultra-stable cysteine-specific bioconjugation chemistry platform using vinyl-pyridine approach, available for licensing against selected targets of interest. Delivers market-leading ADC plasma stability with minimal DAR decrease over time, and is compatible with a broad range of payloads.

Quantifiable outcome

  • IKS014 Phase 1: ORR of 64% in 11 advanced breast cancer patients at doses ≥90 mg/m², including responses in patients previously treated with Enhertu; ORR of 50% in 10 pre-treated HER2+ esophageal cancer patients; clinical benefit rate of 80% in esophageal cancer patients.
  • +3 more outcomes

Companies that use Iksuda Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Iksuda Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Iksuda Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • LegoChem Biosciences (LCB)coreTechnology or Integration · 10 January 2022License and commercialization agreement for LCB's HER2 ADC program (LCB14, now IKS014). Iksuda gained exclusive worldwide rights excluding Greater China and South Korea. Agreement includes development, regulatory, and commercial milestone payments plus royalties on commercial sales. LCB also licensed IKS014 to Fosun Pharma for Greater China.
  • University of GoettingencoreTechnology or Integration · 13 October 2020Exclusive worldwide licensing agreement for a novel class of tumor-activated prodrug payloads with protein alkylating cytotoxicity (ProAlk series). Partnership founded on successful collaboration exemplifying the series in ADC formats. The novel protein alkylating mode of action differs from DNA cross-linking, conferring benefits against drug resistance mechanisms.
  • LegoChem Biosciences (LCB)coreTechnology or Integration · 18 May 2020Licensing agreement for LCB's anti-CD19 ADC program (LCB73, now IKS03) for B-cell cancers including DLBCL and Burkitt lymphoma. Iksuda gained worldwide rights for development and commercialization. IKS03 delivers a tumor-activated prodrug PBD payload with preclinical data showing best-in-class TI over comparators.
  • LegoChem Biosciences (LCB)coreTechnology or Integration · 16 April 2020Multi-target research collaboration and license agreement granting Iksuda access to LCB's next-generation PBD prodrug payload and proprietary linker (ConjuAll platform) for up to three undisclosed targets. Iksuda gained rights to research, develop, and commercialize targeted anti-cancer therapeutics using LCB's technology.
  • LegoChem Biosciences (LCB)coreStrategic or Co-development Partner · 16 April 2020Expanded license agreement granting Iksuda access to LCB's next-generation ADC platform technology for up to six targets, supplementing the tumor-activated payloads accessed in the 2020 licensing agreement. The expansion included LCB's new payload technology.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Iksuda Therapeutics competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Clinical-stage ADC biotech developing ADCs for hematologic and solid tumors, with multiple Phase 1/2 programs and a similar pipeline-based business model. Most directly comparable in stage, modality focus, and go-to-market approach.
  • Mersana Therapeutics: Clinical-stage ADC biotech with proprietary payload platforms (e.g., Dolasynthen, Immunosynthen) targeting oncology. Closely comparable as a platform-based ADC developer with multiple proprietary payload classes and clinical-stage assets.
  • Tubulis: European clinical-stage ADC biotech with proprietary bioconjugation and payload platforms. Highly comparable in technology strategy (proprietary linkers + payloads) and European clinical-stage positioning.
  • Heidelberg Pharma: German clinical-stage ADC biotech with a proprietary amanitin-based payload platform (similar to Iksuda's ProAlk in offering a novel payload MoA). Closely comparable as a European platform-based ADC developer pursuing first-in-class payload differentiation.
  • Bolt Biotherapeutics: Clinical-stage oncology biotech developing immune-stimulating ADCs. Comparable as a clinical-stage ADC innovator with proprietary platform technology, though focused on immune stimulation rather than cytotoxic payloads.
  • Pyxis Oncology: Clinical-stage oncology biotech with ADC and immuno-oncology programs. Comparable as a multi-program clinical-stage ADC developer pursuing novel linker and payload strategies.
  • ProfoundBio: Clinical-stage ADC biotech developing ADCs for solid tumors with proprietary conjugation technology. Comparable in clinical-stage ADC focus and platform-based differentiation approach.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer of ADC technology and developer of Kadcyla (where Iksuda CSO Bob Lutz led development). Acquired by AbbVie in 2024. Broad incumbent reference point for ADC platform validation and competitive context.

Regional players

  • Innovent Biologics: Chinese biopharmaceutical company with a growing ADC pipeline. Comparable as a Chinese-market ADC developer analogous to Fosun Pharma's regional role with IKS014 (FS-1502).

Others

  • WuXi XDC: ADC-focused contract development and manufacturing organization (CDMO). Comparable as an ecosystem participant that supports ADC developers like Iksuda with conjugation and manufacturing services, providing a market context for ADC development economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Iksuda Therapeutics social profiles

Digital presence

Iksuda Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iksuda Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Iksuda Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iksuda Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iksuda Therapeutics

What does Iksuda Therapeutics do?

Iksuda Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Its pipeline includes clinical-stage programs IKS014 (HER2-directed, Phase 1) and IKS03 (CD19-directed, Phase 1) plus preclinical IKS04 and IKS073, all built on the proprietary PermaLink bioconjugation platform, ProAlk protein alkylating payload class, and tumor-selective glucuronide cleavable linkers. The company commercializes its ADC programs and platforms through global licensing deals and independent clinical development.

Is Iksuda Therapeutics a public or private company?

Iksuda Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Iksuda Therapeutics founded?

Iksuda Therapeutics was founded in 2007. It employs 11 to 50 people.

Where is Iksuda Therapeutics based?

Iksuda Therapeutics is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does Iksuda Therapeutics make money?

Three revenue lines are on record. ADC Drug Development & Commercialization is the primary driver. The others are licensing & Partnership Deals and equity Financing.

Who are Iksuda Therapeutics's main competitors?

Direct peers on record are ADC Therapeutics, Mersana Therapeutics, Tubulis, Heidelberg Pharma, Bolt Biotherapeutics, Pyxis Oncology and ProfoundBio. ImmunoGen (AbbVie) is listed as a broad incumbent. Innovent Biologics is listed as a regional player. WuXi XDC is listed as an others.

Does Iksuda Therapeutics have an API?

No public API is recorded for Iksuda Therapeutics.

What industry is Iksuda Therapeutics in?

Iksuda Therapeutics's product category is Antibody-Drug Conjugates (ADC) Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageIksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASHIksuda Therapeutics presented preliminary data from its Phase 1 study of IKS03, a CD19-directed ADC, in advanced B-cell non-Hodgkin lymphoma at ASH. Of 17 efficacy-evaluable patients, 9 responded, yielding a 53% objective response rate, including responses in patients previously treated with CD19-directed CAR-T. Dose escalation is ongoing.AijournIksuda receives US FDA IND clearance for IKS04Iksuda Therapeutics, a UK-based biotechnology company, announced that the U.S. FDA has cleared its Investigational New Drug application for IKS04, a CA242-directed antibody-drug conjugate, enabling Phase 1 clinical trials in patients with gastrointestinal cancers. The drug employs an innovative co-administration approach called the 'IKS04 Regimen,' pairing the ADC with an unconjugated antibody to overcome solid tumour penetration challenges common with highly potent PBD payloads. IKS04 becomes Iksuda's third ADC program to enter clinical development, following IKS014 and IKS03 which are currently in Phase 1 studies.FinancialContent Business PageIksuda receives US FDA IND clearance for IKS04The U.S. Food and Drug Administration has cleared Iksuda Therapeutics' Investigational New Drug application for IKS04, a CA242-directed antibody drug conjugate, enabling Phase 1 trials in patients with gastrointestinal cancers. IKS04 employs a novel pyrrolobenzodiazepine prodrug payload and an innovative co-administration regimen with an unconjugated antibody to overcome solid tumour penetration challenges, representing a first-in-class approach for the ADC field. This marks Iksuda Therapeutics' third ADC program to enter clinical development, following IKS014 and IKS03, which are both currently progressing through Phase 1 studies.MorningstarIksuda receives US FDA IND clearance for IKS04Iksuda Therapeutics received FDA IND clearance for IKS04, a CA242-directed ADC, enabling a Phase 1 trial in GI cancers. The drug uses a novel co-administration regimen with its antibody to improve solid tumor penetration. IKS04 will be the company's third ADC to enter clinical development.BioWorldIksuda’s IKS-04 gains IND clearance for gastrointestinal cancersIksuda Therapeutics obtained FDA IND clearance for IKS-04, an antibody-drug conjugate, enabling a phase I trial in patients with gastrointestinal cancers. The clearance was granted on July 30, 2026, and the trial is now initiated.Business Wire BlogIksuda receives US FDA IND clearance for IKS04Iksuda Therapeutics received FDA IND clearance for IKS04, a CA242-directed antibody drug conjugate, enabling Phase 1 clinical trials in patients with gastrointestinal cancers. The innovative 'IKS04 Regimen' co-administers the ADC with an unconjugated antibody to overcome solid tumour penetration challenges associated with high-potency PBD payloads. IKS04 becomes Iksuda's third ADC program to enter clinical development, with the company noting this milestone further de-risks its novel antibodies, linkers and payloads platforms.PharmiWeb.comIksuda presents encouraging IKS014 Phase 1 data at ESMOIksuda Therapeutics presented Phase 1 data for its HER2-directed antibody drug conjugate IKS014 at the ESMO Congress in Berlin, showing anti-tumour activity across all dose levels in 62 enrolled patients with advanced HER2+ solid tumours. The study demonstrated a 64% objective response rate among breast cancer patients treated at higher doses, with treatment generally well-tolerated up to 120mg/m2 and no maximum tolerated dose reached. The Phase 1 trial is expected to complete in H2 2026, following positive Phase 1 data through Fosun Pharma which is now progressing the same drug (FS-1502) through Phase 3 trials in China.BioSpaceIksuda Presents Encouraging IKS014 Phase 1 Data at ESMOIksuda Therapeutics presented Phase 1 data for its HER2-targeted antibody drug conjugate IKS014 at the ESMO Congress in Berlin, showing anti-tumour activity across all dose levels in 55 evaluable patients with advanced HER2+ solid tumours. In breast cancer patients treated at doses above 90mg/m², an objective response rate of 64% was observed, including responses in patients who had previously received Enhertu. The trial reached 62 enrolled patients with no maximum tolerated dose reached, and dose expansion studies are planned in the US, Australia, New Zealand and Singapore ahead of an expected Phase 1 completion in H2 2026.Business Wire BlogIksuda Presents Encouraging IKS014 Phase 1 Data at ESMOIksuda Therapeutics presented Phase 1 data for IKS014, its HER2-directed antibody drug conjugate, at the European Society for Medical Oncology Congress in Berlin, Germany. The dose escalation study enrolled 62 patients at Australian sites and demonstrated anti-tumour activity across all dose levels, including a 64% objective response rate among breast cancer patients at doses above 90mg/m², with responses observed even in patients previously treated with Enhertu. The drug was generally well-tolerated with no maximum tolerated dose reached, and the Phase 1 trial is expected to complete in H2 2026.